PRNewsWire
04 Jun 2026, 20:36 UTC · 2h ago
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
PRNewsWire
04 Jun 2026, 20:36 UTC · 2h ago
Story key points
2 claims · impact-rated
A federal securities lawsuit alleges that setrusumab increases bone density but does not correlate to a decrease in annualized fracture rates. — This challenges the core clinical efficacy of a key product candidate, which could significantly impair its path to approval and commercial value.
-0.80Kuehn Law is investigating whether officers and directors of Ultragenyx Pharmaceutical Inc. breached their fiduciary duties by misrepresenting the potential of setrusumab. — Legal action and allegations of corporate misconduct create governance risks and potential financial liabilities for the company.
-0.40Ticker attribution
Model heads
The company is mentioned as the subject of a shareholder litigation investigation for potential breach of fiduciary duties.
Continue reading
6 related stories
Search tags
The company is facing a shareholder litigation investigation regarding alleged misrepresentations of drug potential and breach of fiduciary duties.
The company is mentioned as the subject of a shareholder litigation investigation for potential breach of fiduciary duties.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
4 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
PRNewsWire
1h ago
